Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cardiac Adrenergic Nervous System and Left Ventricular Remodeling

Cardiac Adrenergic Nervous System and Left Ventricular Remodeling REVIEW ARTICLE Cardiac Adrenergic Nervous System and Left Ventricular Remodeling Rohan Samson, MD, Hassan Baydoun, MD, Abhishek Jaiswal, MD and Thierry H. Le Jemtel, MD plantation, the only other intervention that restores normal LV Abstract: Heightened cardiac adrenergic nervous system (ANS) performance (Figure 1). activity and progression of left ventricular (LV) remodeling are The unique effect of long-term BARB on LV remodeling temporally related in patients with systolic heart failure. Whether has fostered research on the cardiac adrenergic nervous system cardiac ANS activation directly contributes to or merely accompanies (ANS), including activation, downstream signaling pathways LV remodeling remains an unresolved issue. Human and experimental and alternative approaches to reversing/lessening progression of data that directly link cardiac ANS activation to LV remodeling and 17–20 LV dysfunction. The present review focuses on cardiac worsening heart failure are first reviewed, including cardiac norepi- ANS activation, beta adrenergic receptor signaling pathway nephrine spillover. Alterations of beta adrenergic receptor signaling alterations and novel approaches to cardiac ANS deactivation pathways are then addressed with emphasis on the mechanisms that in systolic HF. may mediate the beneficial effect of beta adrenergic receptor blockade on LV remodeling. Lastly, alternative approaches to beta adrenergic CARDIAC ANS ACTIVATION receptor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of the Medical Sciences Wolters Kluwer Health

Cardiac Adrenergic Nervous System and Left Ventricular Remodeling

Le Jemtel, Thierry H.
American Journal of the Medical Sciences , Volume Publish Ahead of Print – Sep 1, 2015
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/cardiac-adrenergic-nervous-system-and-left-ventricular-remodeling-3hIWZthu0Q

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 by the Southern Society for Clinical Investigation.
ISSN
0002-9629
eISSN
1538-2990
DOI
10.1097/MAJ.0000000000000549
pmid
26332730
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Cardiac Adrenergic Nervous System and Left Ventricular Remodeling Rohan Samson, MD, Hassan Baydoun, MD, Abhishek Jaiswal, MD and Thierry H. Le Jemtel, MD plantation, the only other intervention that restores normal LV Abstract: Heightened cardiac adrenergic nervous system (ANS) performance (Figure 1). activity and progression of left ventricular (LV) remodeling are The unique effect of long-term BARB on LV remodeling temporally related in patients with systolic heart failure. Whether has fostered research on the cardiac adrenergic nervous system cardiac ANS activation directly contributes to or merely accompanies (ANS), including activation, downstream signaling pathways LV remodeling remains an unresolved issue. Human and experimental and alternative approaches to reversing/lessening progression of data that directly link cardiac ANS activation to LV remodeling and 17–20 LV dysfunction. The present review focuses on cardiac worsening heart failure are first reviewed, including cardiac norepi- ANS activation, beta adrenergic receptor signaling pathway nephrine spillover. Alterations of beta adrenergic receptor signaling alterations and novel approaches to cardiac ANS deactivation pathways are then addressed with emphasis on the mechanisms that in systolic HF. may mediate the beneficial effect of beta adrenergic receptor blockade on LV remodeling. Lastly, alternative approaches to beta adrenergic CARDIAC ANS ACTIVATION receptor

Journal

American Journal of the Medical Sciences – Wolters Kluwer Health

Published: Sep 1, 2015

References

  • 2013 ACCF/AHA guideline for the management of heart failure
    Yancy
  • Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure
    Bristow
  • Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after β-blocker therapy
    de Groote
  • Reverse remodeling in heart failure—fact or fiction?
    Pieske
  • Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group
    Flather
  • The Heart outcomes prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
    Yusuf
  • Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators
    Konstam
  • The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    Pitt
  • Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Pitt
  • Eplerenone in patients with systolic heart failure and mild symptoms
    Zannad
  • Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats
    Dorrance
  • Remodeling and recovery following myocardial infarction
    Solomon
  • Randomized, double-blind, Multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with Eplerenone on ventricular remodeling in patients with mild to moderate heart failure and left ventricular systolic dysfunction
    Udelson
  • Angiotensin-neprilysin inhibition versus enalapril in heart failure
    McMurray
  • Resolution of left bundle branch block-induced cardiomyopathy by cardiac resynchronization therapy
    Vaillant
  • Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment
    Merlo
  • The 2009 Carl Ludwiig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to management
    Esler
  • The autonomic nervous system and heart failure
    Florea
  • Adrenergic nervous system in heart failure: pathophysiology and therapy
    Lymperopoulos
  • Antiadrenergic therapy of chronic heart failure: surprises and new opportunities
    Bristow
  • GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling
    Reiter
  • Trafficking of G Protein-Coupled receptors
    Drake
  • β-Arrestin: a protein that regulates β-adrenergic receptor function
    Lohse
  • Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart
    Ungerer
  • Sympathetic nervous system activation in human heart failure
    Floras
  • The sympathetic nervous system in heart failure
    Triposkiadis
  • The autonomic nervous system and hypertension
    Mancia
  • Novel mechanisms of sympathetic regulation in chronic heart failure
    Zucker
  • Central angiotensin AT1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure
    Ramchandra
  • Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure
    Chidsey
  • Myocardial norepinephrine concentration in man. Effects of reserpine and of congestive heart failure
    Chidsey
  • Plasma norepinephrine in congestive heart failure
    Thomas
  • Cardiac sympathetic nervous system function in congestive heart failure
    Eisenhofer
  • Evidence for reduction of norepinephrine uptake sites in the failing human heart
    Böhm
  • The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation
    Backs
  • Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure
    Runqvist
  • Basis for the preferential activation of cardiac sympathetic nerve activity in heart failure
    Ramchandra
  • Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study
    Gronda
  • Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure
    Brunner-La Rocca
  • Adverse Consequences of high sympathetic nervous system activity in the failing human heart
    Kaye
  • Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
    Cohn
  • Norepinephrine spillover to plasma during steady-state supine bicycle exercise: comparison of patients with congestive heart failure and normal subjects
    Hasking
  • Adrenergic effects on the biology of the adult mammaliian cardiocyte
    Mann
  • Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts
    Bristow
  • Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure
    Bristow
  • Beta 2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation
    Nikolaev
  • Phosphodiesterase type 5: expanding roles in cardiovascular regulation
    Kass
  • Role of cGMP Signaling and Phosphodiesterase-5 inhibitors in Cardioprotection
    Kukreja
  • Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
    Tsai
  • cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism
    Takimoto
  • Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure
    Senzaki
  • Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans
    Borlaug
  • Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T
    Hassan
  • Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents
    Lowes
  • Therapeutic molecular phenotype of β-blocker-associated reverse-remodeling in nonischemic dilated cardiomyopathy
    Kao
  • Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade
    Iaccarino
  • What is the role of beta-adrenergic signaling in heart failure?
    Lohse
  • Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
    Gilbert
  • Clinical effects of β-adrenergic blockade in chronic heart failure. A meta-analysis of double-Blind, placebo-controlled randomized trials
    Lechat
  • The molecular basis for distinct beta adrenergic receptor subtype actions in cardiomyocytes
    Steinberg
  • Beta-blockers in heart failure
    Cohn
  • effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
    MERIT-HF Study Group
  • Meta-analysis beta blocker dose, heart rate reduction, and death in patients with heart failure
    McAlister
  • Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction, and death in patients with systolic heart failure receiving beta- blockers
    Flannery
  • Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure
    Reiken
  • Calmodulin- dependent protein kinase II: linking heart failure and Arrhythmias
    Swaminathan
  • Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice
    Shan
  • A tale of two leaks
    Venetucci
  • Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis
    Schleman
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy
    Bello
  • Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure
    Small
  • Cardiac sympathetic imaging with mIBG in heart failure
    Carrió
  • Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal
    Perrone-Filardi
  • Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial imaging for Risk evaluation in Heart Failure) study
    Jacobson
  • Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a β-ARK inhibitor
    Koch
  • Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice
    Rockman
  • Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure
    Harding
  • AAV6 betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model
    Raake
  • Myocardial adeno-associated virus serotype 6-bARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure
    Rengo
  • Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID) a phase 2 trial of Intracoronary gene therapy of sarcoplasmic Reticuum Ca2+ -ATPase in patients with advanced heart failure
    Jessup
  • Restoration of mechanical and energetic function in failing aortic- banded rat hearts by gene transfer of calcium cycling proteins
    Sakata
  • Peptide inhibitors of G protein-coupled receptor kinases
    Winstel
  • An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro
    Mayer
  • Differential targeting of Gβγ-subunit signaling with small molecules
    Bonacci
  • Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure
    Casey